The Correlation of Enhanced Osteogenic Capability in Titanium Alloy Implants Through Modulation of the Runx2/ BSP Pathway
Journal of Cellular and Molecular Medicine · 2026-07 · 30 (13)
DOI: 10.1111/jcmm.71254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 09.07.2026. Verfasst von Zhuo Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Titanium, Osteogenesis, Core Binding Factor Alpha 1 Subunit, Integrin-Binding Sialoprotein. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We investigated the mechanical properties, biocompatibility and osteogenic potential of titanium alloy implants (Ti6Al4V group) compared to conventional alloy implants (Ti4Al2V group). The mechanical performance tests, including ultimate tensile strength, elongation at break, yield strength and ultimate compressive strength, demonstrated superior results for the titanium alloy implants. In vitro cell experiments, comprising CCK‐8 assay and ALP (alkaline phosphatase) staining, revealed significantly higher cell viability and osteogenic activity in the Ti6Al4V group. Additionally, in vivo animal experiments, including HE staining, flow cytometry, immunofluorescence assay. Ti‐6Al‐4V implants exhibited superior mechanical properties compared with conventional alloy implants, with a higher ultimate tensile strength (1200 ± 50 vs. 950 ± 45 MPa), greater elongation at break (15.2% ± 2.1% vs. 9.8% ± 1.7%), higher compressive yield strength (850 ± 40 vs. 720 ± 35 MPa) and higher ultimate compressive strength (1300 ± 60 vs. 1100 ± 50 MPa) (all p < 0.05). The elastic modulus of Ti‐6Al‐4V (10.8 ± 0.15 GPa) was lower than that of the conventional alloy (16.2 ± 0.18 GPa), closer to cancellous bone (~4 GPa), suggesting reduced stress shielding. In vitro, Ti‐6Al‐4V implants supported significantly higher MC3T3‐E1 proliferation at 48 h ( p < 0.01) and enhanced osteogenic differentiation, with ALP staining intensity of 450 ± 35 vs. 320 ± 28 and a higher percentage of ALP‐positive cells (85% ± 4% vs. 60% ± 5%) compared with controls (both p < 0.05). In vivo, H&E staining showed more abundant and better‐organised bone trabeculae around Ti‐6Al‐4V implants, while flow cytometry revealed reduced apoptosis in peri‐implant tissues ( p < 0.05). At the molecular level, Ti‐6Al‐4V implants significantly upregulated osteogenic markers: Runx2 protein expression was increased by 33% and BSP by 42% relative to the control alloy, accompanied by higher levels of osteocalcin (OCN) and collagen type I alpha 1 (COL1A1) (all p < 0.05). Ti4Al2V groupTi4Al2V group. These findings suggest that titanium alloy implants exhibit better biocompatibility and osteogenic capacity than conventional alloy implants, providing a strong foundation for their potential application in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stomatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Huayan Guo
Zitieren
APA
Wang, Z., & Guo, H. (2026). The Correlation of Enhanced Osteogenic Capability in Titanium Alloy Implants Through Modulation of the Runx2/ BSP Pathway. Journal of Cellular and Molecular Medicine, 30(13). https://doi.org/10.1111/jcmm.71254
Vancouver
Wang Z, Guo H. The Correlation of Enhanced Osteogenic Capability in Titanium Alloy Implants Through Modulation of the Runx2/ BSP Pathway. Journal of Cellular and Molecular Medicine. 2026;30(13). doi:10.1111/jcmm.71254
BibTeX
@article{Wang2026,
author = {Wang, Zhuo and Guo, Huayan},
title = {The Correlation of Enhanced Osteogenic Capability in Titanium Alloy Implants Through Modulation of the Runx2/ BSP Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {13},
doi = {10.1111/jcmm.71254}
}
EUVIMED